Potential vaccine Novavax will complete its Phase 3 clinical trial in the UK. If the vaccines are proven to be safe and effective they could be delivered to the UK by the middle of next year. There are now plans to manufacture the COVID-19 vaccine in the UK and gain access to 60 million doses.
The UK will also co-fund a global clinical trial with the Janssen Pharmaceutical Companies of Johnson & Johnson which will account for the other 30 million doses.
Priority would be given to groups such as health and social care workers and those with conditions that put them at higher risk from the coronavirus.
With the two new deals, the UK has secured access to six vaccine candidates.
US drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.
The company and the UK government will collaborate for the trial to assess the efficacy of the vaccine in the UK population, Novavax said in a statement, but did not disclose any financial details of the agreement.
The trial will be a study in about 9,000 adults between 18 years and 85 years of age.
Novavax would partner with Fujifilm Diosynth Biotechnologies for manufacturing the antigen component of its COVID-19 vaccine candidate in the UK, it added.
READ MORE: Supertrawler plot: Brexit free-for-all - warning ships STAKING CLAIM
The company is also gearing up to deliver 100 million doses to the United States by January after it was awarded $1.6 billion to cover testing and manufacturing of its potential vaccine in the country.
Novavax has received $2 billion in funding so far for its coronavirus vaccine, including $384 million from the Coalition for Epidemic Preparedness Innovations (CEPI).
The NVX-CoV2373 doses will be supplied to the UK beginning as early as the first quarter of 2021, while phase 3 trial is expected to begin in the third quarter of this year, the company said.
DON'T MISS
'So you don't know!' Tory clashes with Sky host over vaccination issue [CLASH]
Coronavirus vaccine: Imperial's first trial to take off next month [UPDATE]
Coronavirus vaccine: Expert reveals 'exciting' update but has warning [WARNING]
The Fujifilm Diosynth Biotechnologies site in the UK is expected to produce about 180 million doses annually, it added.
The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines, as the race to develop a safe and effective vaccine reaches the final stages of testing.
There are currently no approved vaccines for COVID-19, with over 25 candidates being studied in humans.
In an early-stage trial, Novavax's vaccine candidate, NVX-CoV2373, has produced higher levels of antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients and the vaccine was "well tolerated" overall.
We believe that Novavax has a highly innovative vaccine that could be the first in its class of protein-based vaccine options.
Kate Bingham, Chair of the UK Government's Vaccines Taskforce, said: "It is encouraging that Novavax' recent clinical data shows their vaccine triggers an immune response greater than that in patients who have recovered from the disease.
"We believe that Novavax has a highly innovative vaccine that could be the first in its class of protein-based vaccine options.
"We are happy to partner with them and global organisations such as CEPI to further our mutual commitments to ensure global access to the vaccine."
Ms Bingham said also confirmed the separate vaccine deal, for 30 million doses, with drug manufacturers Johnson & Johnson.
The advance purchase agreement will also provide an option for an additional purchase of up to a 22 million doses.
J&J said it has also agreed to collaborate with the UK government on a global Phase 3 trial to explore the two-dose regimen of its vaccine candidate.
The trial will run parallel to the Phase 3 trial investigating the single-dose programme.
Paul Found, Chief Operating Officer, FUJIFILM Diosynth Biotechnologies, UK site, said: "To change the course of the pandemic, FUJIFILM Diosynth Biotechnologies is excited to expand our partnership with Novavax to manufacture their COVID-19 vaccine candidate at our UK site.
"We are honored to support the UK government and Novavax with the shared goal of delivering a safe and effective vaccine to the British people."
Stanley C Erck, President and Chief Executive Officer of Novavax, said: "Our Phase 3 clinical trial in the UK will be a critical component to assess the efficacy of NVX-CoV2373, which in a Phase 1 trial has already demonstrated to be generally well-tolerated and to elicit robust antibody responses.
"We are also delighted to expand our collaboration with FUJIFILM Diosynth Biotechnologies to manufacture our antigen at its UK site."
The treatments could be delivered to the UK next year if tests prove them to be safe and reliable.
With six deals each so far, Britain and the United States are leading the global race to strike deals with drugmakers for vaccines.
The latest agreements bring the UK's total number of doses secured to 362 million for the population of 66 million.
The race to develop a vaccine is arguably the most hotly contested in the history of pharmaceutical technology.
Earlier this week, Russian President Vladimir Putin claimed his country was ready to deploy its own vaccine, which had already been administered to his own daughter.
Vietnam's health ministry has registered to buy the vaccine, state television reported today, as the Southeast Asian country fights a new outbreak of the coronavirus following months of no local cases.
However, the move has been criticised by among others Ms Bingham, who today told Sky News there was no proof Russia's vaccine would actually work.
Meanwhile, today researchers announced a coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials.
There are currently 20,907,410 confirmed cases of COVID-19 worldwide, according to Johns Hopkins University's Coronavirus Resource Centre, including 315,600 in the UK.
https://news.google.com/__i/rss/rd/articles/CBMifWh0dHBzOi8vd3d3LmV4cHJlc3MuY28udWsvbmV3cy91ay8xMzIyNjkwL0Nvcm9uYXZpcnVzLW5ld3MtdmFjY2luZS1VSy1ub3ZhdmF4LWFjY2Vzcy1kb3Nlcy1DT1ZJRC0xOS1zZWNvbmQtd2F2ZS1ib3Jpcy1qb2huc29u0gGBAWh0dHBzOi8vd3d3LmV4cHJlc3MuY28udWsvbmV3cy91ay8xMzIyNjkwL0Nvcm9uYXZpcnVzLW5ld3MtdmFjY2luZS1VSy1ub3ZhdmF4LWFjY2Vzcy1kb3Nlcy1DT1ZJRC0xOS1zZWNvbmQtd2F2ZS1ib3Jpcy1qb2huc29uL2FtcA?oc=5
2020-08-14 06:04:00Z
52780994000895
Tidak ada komentar:
Posting Komentar